v3.25.2
Condensed Consolidated Statements Of Cash Flows (Unaudited) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Operating Activities    
Net Income (Loss) $ (63) $ 777
Non-cash reconciliation adjustments:    
Depreciation, amortization and accretion (Note 16) 141 144
Unrealized (gains) losses on derivative instruments (Note 2) 103 36
Deferred income taxes (66) 94
Nuclear fuel amortization (Note 7) 44 63
Nuclear decommissioning trust funds (gain) loss, net (excluding interest and fees) (Note 6) (44) (80)
(Gain) loss on AWS Data Campus Sale and ERCOT Sale (Note 17) 0 (886)
Other (Note 16) 34 (58)
Changes in assets and liabilities:    
Accounts receivable (103) (14)
Inventory, net 78 90
Other assets 15 34
Accounts payable and accrued liabilities (57) (114)
Accrued interest 12 (1)
Collateral received (posted), net (58) 35
Other liabilities (101) 30
Net cash provided by (used in) operating activities (65) 150
Investing Activities    
Nuclear decommissioning trust funds investment purchases (Note 6) (1,201) (1,110)
Nuclear decommissioning trust funds investment sale proceeds (Note 6) 1,186 1,095
Property, plant and equipment expenditures (Note 7) (51) (45)
Nuclear fuel expenditures (Note 7) (50) (44)
Proceeds from AWS Data Campus Sale and ERCOT Sale (Note 17) 0 1,089
Other 2 (6)
Net cash provided by (used in) investing activities (114) 979
Financing Activities    
Share repurchases (Note 15) (103) (654)
Revolving credit facility borrowings (Note 10) 75 0
Revolving credit facility repayments (Note 10) (5) 0
Debt repayments (Note 10) (9) 0
Deferred financing costs (9) 0
Cumulus Digital TLF repayment 0 (182)
Repurchase of noncontrolling interest 0 (39)
Cash settlement of restricted stock units 0 (28)
Other 0 (12)
Net cash provided by (used in) financing activities (51) (915)
Net increase (decrease) in cash and cash equivalents and restricted cash and cash equivalents (230) 214
Beginning of period cash and cash equivalents and restricted cash and cash equivalents 365 901
End of period cash and cash equivalents and restricted cash and cash equivalents $ 135 $ 1,115